Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Participated in Either EFC18418 or EFC18419 Clinical Studies

NCT07424144 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07424144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07424144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded Extension Study to Evaluate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Participated in Either EFC18418 or EFC18419 Clinical Studies
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 12, 2026
Completion date
February 17, 2027
Enrollment
59 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

chronic rhinosinusitis with nasal polyps